An ROS‐Responsive CeO 2 –Selenium Nanozyme Mitigates Renal Injury via Coordinated Ferroptosis Inhibition and Inflammation Resolution
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Zhiwen Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Ferroptosis, Acute Kidney Injury, Cerium, Reactive Oxygen Species. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Hubei Province, Key Research and Development Program of Wuhan City.
Abstract (Originalsprache)
Acute kidney injury (AKI) and chronic kidney disease (CKD), despite distinct etiologies, share a common pathological axis characterized by reactive oxygen species (ROS) burst, ferroptosis activation, and sustained inflammation. Targeting this ROS–ferroptosis–inflammation cycle represents a promising therapeutic strategy; however, current nanoplatforms are limited by insufficient responsiveness and limited capacity to regulate shared pathological mechanisms across distinct renal disease models. Here, we develop an engineered ROS‐responsive nanozyme by integrating diselenide‐bridged organosilica, hyaluronic acid (HA)‐modified cerium oxide (CeO 2 ), and a selenium‐containing diselenide framework. Under oxidative stress, MON@HA‐CeO 2 undergoes ROS‐triggered disassembly, coupling HA‐CeO 2 ‐mediated ROS scavenging with selenium‐related GPX4 restoration to suppress lipid peroxidation, ferroptosis, and inflammatory amplification. In both glycerol‐induced AKI and unilateral ureteral obstruction (UUO)‐induced renal fibrosis models, the nanozyme significantly improves renal function and attenuates tissue injury, fibrosis, and inflammation. Overall, this work demonstrates a versatile strategy for targeting a shared pathological axis and provides a promising platform for the treatment of diverse renal diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Min Yang, Chun Zhang
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Hubei Province
- Key Research and Development Program of Wuhan City
- China Postdoctoral Science Foundation
- Traditional Chinese Medicine Scientific Research Project of Hubei Provincial Administration of Traditional Chinese Medicine
Zitieren
APA
Wang, Z., Xie, Y., Zhang, J., Yang, M., Zou, Z., & Zhang, C. (2026). An ROS‐Responsive CeO 2 –Selenium Nanozyme Mitigates Renal Injury via Coordinated Ferroptosis Inhibition and Inflammation Resolution. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71771
Vancouver
Wang Z, Xie Y, Zhang J, Yang M, Zou Z, Zhang C. An ROS‐Responsive CeO 2 –Selenium Nanozyme Mitigates Renal Injury via Coordinated Ferroptosis Inhibition and Inflammation Resolution. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71771
BibTeX
@article{Wang2026,
author = {Wang, Zhiwen and Xie, Yue and Zhang, Jiahui and Yang, Min and Zou, Zhiyue and Zhang, Chun},
title = {An ROS‐Responsive CeO 2 –Selenium Nanozyme Mitigates Renal Injury via Coordinated Ferroptosis Inhibition and Inflammation Resolution},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71771}
}
EUVIMED